ArticleThe Journal of infectious diseases2015
Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Systemic and Mucosal Antibody Responses Against Neisseria gonorrhoeae (Ng) Outer Membrane Vesicle Antigens following Four-Component Meningococcal Serogroup B (4CMenB) Immunization in Healthy Adults: A Randomized Phase II Trial.Nature communications · 2026Trial
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
- Multifunctional antibody responses from a primateScience translational medicine · 2026Article
- Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.NPJ vaccines · 2026Article
- Review
- Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design.bioRxiv : the preprint server for biology · 2025Article
- Contribution of the different Neisseria gonorrhoeae lipooligosaccharide structural variants to functional responses elicited by GMMA outer membrane vesicles.NPJ vaccines · 2025Article
- Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by Neisseria gonorrhoeae via effects on sialic acid metabolism.Cell host & microbe · 2025Article
- A novel GMMA-based gonococcal vaccine demonstrates functional immune responses in mice.NPJ vaccines · 2025Article
- Mechanisms of antibody-dependent enhancement of infectious disease.Nature reviews. Immunology · 2025Review
- PreclinicalFrontiers in immunology · 2025Article
- Gonococcal PorB: a multifaceted modulator of host immune responses.Trends in microbiology · 2024Review
- Review
- In Vitro Pre-Clinical Evaluation of a Gonococcal Trivalent Candidate Vaccine Identified by Transcriptomics.Vaccines · 2023Article
- Immune responses toFrontiers in immunology · 2023Review
- Strategies for successful designing of immunocontraceptive vaccines and recent updates in vaccine development against sexually transmitted infections - A review.Saudi journal of biological sciences · 2022Review
- Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.The Journal of infectious diseases · 2022Article
- Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.Vaccines · 2021Review
- Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.Infection and immunity · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibodies against reduction modifiable protein (anti-Rmp Abs) can block complement-dependent killing of Neisseria gonorrhoeae by otherwise bactericidal Abs. An anti-lipooligosaccharide bactericidal monoclonal Ab (mAb) 2C7, a gonococcal vaccine candidate Ab, attenuates vaginal colonization by gonococci in BALB/c mice. Here we show that anti-Rmp Abs block the efficacy of mAb 2C7 in mice in a dose-dependent manner. Anti-Rmp Abs also counteract 2C7-mediated enhancement of C3 deposition on gonococci in vivo. The mouse model will prove useful to study how blocking Abs influence the efficacy of gonococcal vaccines. Preexisting anti-Rmp Abs will be an important consideration in evaluating the efficacy of gonococcal vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.